Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -37.11% is 968% below its 5-year average of 4.27%, near the low end of its 5-year range (-38.38%–111.61%).
954.09% below its 12-month average of 4.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.09%.
RETURN ON ASSETS (ROA)
-37.11%
RETURN ON ASSETS (ROA) AVG TTM
4.34%
RETURN ON ASSETS (ROA) AVG 3Y
-11.90%
RETURN ON ASSETS (ROA) AVG 5Y
4.27%
RETURN ON ASSETS (ROA) AVG 10Y
-15.65%
RETURN ON ASSETS (ROA) AVG 15Y
-29.36%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-954.09%
CURRENT VS 3Y AVG
-211.91%
CURRENT VS 5Y AVG
-968.41%
CURRENT VS 10Y AVG
-137.10%
CURRENT VS 15Y AVG
-26.42%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.22%
median of 525 covered companies
CURRENT VS SECTOR MEDIAN
-31.50%
vs the sector median at left
Agios Pharmaceuticals, Inc.
Market Cap
$1.84B
Return on Assets (ROA)
-37.11%
TTM Avg
4.34%
3Y Avg
-11.90%
5Y Avg
4.27%
Market Cap
$1.86B
Return on Assets (ROA)
10.25%
TTM Avg
8.68%
3Y Avg
8.17%
5Y Avg
8.38%
Market Cap
$1.86B
Return on Assets (ROA)
1.78%
TTM Avg
2.10%
3Y Avg
3.84%
5Y Avg
3.40%
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
Market Cap
$1.80B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
Market Cap
$1.76B
Return on Assets (ROA)
-61.53%
TTM Avg
-47.53%
3Y Avg
-47.53%
5Y Avg
-47.53%
Market Cap
$1.74B
Return on Assets (ROA)
3.18%
TTM Avg
-8.22%
3Y Avg
-16.26%
5Y Avg
-17.13%
Market Cap
$1.72B
Return on Assets (ROA)
-10.49%
TTM Avg
-13.41%
3Y Avg
-10.26%
5Y Avg
-6.23%
Market Cap
$1.99B
Return on Assets (ROA)
-11.05%
TTM Avg
-19.34%
3Y Avg
-25.88%
5Y Avg
-26.23%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.84B | -37.11% | 4.34% | -11.90% | 4.27% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.86B | 10.25% | 8.68% | 8.17% | 8.38% |
| Astrana Health, Inc. (ASTH)vs › | $1.86B | 1.78% | 2.10% | 3.84% | 3.40% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.80B | -46.66% | -46.30% | -40.19% | -33.55% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.76B | -61.53% | -47.53% | -47.53% | -47.53% |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 3.18% | -8.22% | -16.26% | -17.13% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.72B | -10.49% | -13.41% | -10.26% | -6.23% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.99B | -11.05% | -19.34% | -25.88% | -26.23% |
| Immunome, Inc. (IMNM)vs › | $1.99B | -44.98% | -76.52% | -94.59% | -76.85% |
ROA
-37.1%
ROE
-40.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -31.82% |
| 2024-12-31 | 40.51% |
| 2023-12-31 | -37.57% |
| 2022-12-31 | -18.71% |
| 2021-12-31 | 111.61% |
| 2020-12-31 | -38.38% |
| 2019-12-31 | -46.19% |
| 2018-12-31 | -40.31% |
| 2017-12-31 | -51.22% |
| 2016-12-31 | -32.06% |
| 2015-12-31 | -28.03% |
| 2014-12-31 | -10.88% |
| 2013-12-31 | -19.59% |
| 2012-12-31 | -14.67% |
| 2011-12-31 | -12.19% |
